November 2, 2012 – A clinical trial that compared catheter-based PFO closure using an investigational device found that there was no significant reduction in ischemic and bleeding events compared to standard medical therapy; stroke risk was non-significantly reduced with device therapy.

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible heart attack; conversely, patients with higher levels of platelet inhibition are at greater risk for bleeding complications.

November 1, 2012 — TomTec Imaging Systems GmbH announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its new 2-D Cardiac Performance Analysis MR (2-D CPA MR) software solution for magnetic resonance imaging (MRI).

HIMMS Electronic Medical Records Information Technology

November 1, 2012 — HIMSS opposes the Oct. 4 call from four House Republican leaders for the Department of Health and Human Services (HHS) to “immediately suspend the distribution of incentive payments until [the department] promulgates universal interoperable standards.”

Medtronic Inc. announced promising data from the Engager European Pivotal Trial for the investigational Medtronic Engager transcatheter aortic valve implantation (TAVI) system. The first results from the multi-center trial support the safety and clinical performance of the valve, which uses a transapical delivery approach to treat patients with severe aortic stenosis who were at high or extreme risk for surgical aortic valve replacement (SAVR).

November 1, 2012 — It looks as though drug-eluting balloons (DEBs), already widely used in Europe, are set to burst into the global market as heart conditions become a more common problem, states a new report by healthcare experts GBI Research.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now